A Case of Grover’s Disease Secondary to Brodalumab Therapy for Psoriasis-Reference-Cited by-同舟云学术

A Case of Grover’s Disease Secondary to Brodalumab Therapy for Psoriasis

Published:2020-11-03 Issue:1 Volume:6 Page:16-18
ISSN:2475-5303
Container-title:Journal of Psoriasis and Psoriatic Arthritis
language:en
Short-container-title:Journal of Psoriasis and Psoriatic Arthritis

Author:

Muzumdar Sonal¹^ORCID,Radfar Arash²,Payette Michael³

Affiliation:

1. University of Connecticut School of Medicine, Farmington, CT, USA

2. Inform Diagnostics, Irving, TX, USA

3. Central Connecticut Dermatology, Cromwell, CT, USA

Abstract

Background:Grover’s disease has been associated with a number of medications including sulfadoxine-pyrimethamine, recombinant interleukin (IL)-4, ipilimumab, and BRAF inhibitors. To our knowledge, Grover’s disease has not been reported in association with interleukin-17 inhibitors.Case Description:A 47-year-old female with plaque psoriasis developed Grover’s disease 3 months following initiation of brodalumab. Discontinuation of brodalumab and initiation of certolizumab pegol and methotrexate led to resolution of her rash.Conclusion:This case highlights Grover’s disease as a potential adverse effect of brodalumab therapy. In patients who develop Grover’s disease with brodalumab, modification of therapy may be considered due to the bothersome nature of the rash.

Publisher

SAGE Publications

Subject

Dermatology,Rheumatology

Link

http://journals.sagepub.com/doi/pdf/10.1177/2475530320970530

Reference10 articles.

1. Grover Disease (Transient Acantholytic Dermatosis)

2. Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy

3. A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1

4. Transient acantholytic dermatosis (Grover's disease) in a patient with progressive systemic sclerosis treated with D-peniciliamine